In terms of trials targeting BAs or their receptors, there is currently a recruiting phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT04956328) investigating obeticholic acid, a farnesoid X receptor agonist, and its effects on liver function in patients with primary biliary cirrhosis. This evidence concerns the gene NR1H4 and primary biliary cholangitis.